Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephrotic syndrome.
Shimizu M, Khoshnoodi J, Akimoto Y, Kawakami H, Hirano H, Higashihara E, Hosoyamada M, Sekine Y, Kurayama R, Kurayama H, Joh K, Hirabayashi J, Kasai K, Tryggvason K, Ito N, Yan K. Shimizu M, et al. Among authors: higashihara e. Lab Invest. 2009 Feb;89(2):178-95. doi: 10.1038/labinvest.2008.125. Epub 2008 Dec 15. Lab Invest. 2009. PMID: 19079321 Free article.
Amino acid transporter LAT3 is required for podocyte development and function.
Sekine Y, Nishibori Y, Akimoto Y, Kudo A, Ito N, Fukuhara D, Kurayama R, Higashihara E, Babu E, Kanai Y, Asanuma K, Nagata M, Majumdar A, Tryggvason K, Yan K. Sekine Y, et al. Among authors: higashihara e. J Am Soc Nephrol. 2009 Jul;20(7):1586-96. doi: 10.1681/ASN.2008070809. Epub 2009 May 14. J Am Soc Nephrol. 2009. PMID: 19443642 Free PMC article.
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators. Gansevoort RT, et al. Among authors: higashihara e. Kidney Int. 2019 Jul;96(1):159-169. doi: 10.1016/j.kint.2018.11.044. Epub 2019 Mar 9. Kidney Int. 2019. PMID: 30898339 Free PMC article. Clinical Trial.
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants. Chapman AB, et al. Kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18. Kidney Int. 2015. PMID: 25786098 Free PMC article.
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, Leliveld AM, Ouyang J, Perrone RD, Torres VE, Gansevoort RT; TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3:4 Trial Investigators. Casteleijn NF, et al. Among authors: higashihara e. Am J Kidney Dis. 2017 Feb;69(2):210-219. doi: 10.1053/j.ajkd.2016.08.028. Epub 2016 Nov 14. Am J Kidney Dis. 2017. PMID: 27856088 Free PMC article. Clinical Trial.
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, Higashihara E, Harris PC, Zhou W, Ouyang J, Czerwiec FS, Torres VE. Irazabal MV, et al. Among authors: higashihara e. Kidney Int Rep. 2016 Aug 6;1(4):213-220. doi: 10.1016/j.ekir.2016.08.001. eCollection 2016 Nov. Kidney Int Rep. 2016. PMID: 29142926 Free PMC article.
212 results